The glucose injections of Haussen and Zhengdafeng Heliamine were approved on the same day

Pharmaceutical Network December 31st, the State Drug Administration's official website shows that Jiangsu Haussen Pharmaceuticals' lynazine glucose injection and Jiangsu Zhengda Fenghai Pharmaceutical's lynazine glucose injection to supplement the application was approved on the same day.
2019 sales of end-of-life lynazine injections in China's public medical institutions exceeded 1.8 billion yuan, according to the Company's internal network data, and growth slowed in the first half of this year.
10 pharmaceutical companies such as Jiangsu Hausen Pharmaceuticals, Zhengda Tianqing Pharmaceuticals, Jiangsu Zhengda Fenghai Pharmaceuticals, etc.
, Pfizer has the largest market share, accounting for more than 50 per cent, followed by Jiangsu Haussen Pharmaceuticals with 33.58 per cent.
, no company had been approved for the product.
December 29, 2020 drug approval documents to be received information release data show that lysine is a new synthetic antibiotic, can inhibit bacterial protein synthesis, comprehensive coverage of Glollaton-positive coli, with other antimicrobial drugs almost no cross-resistance, and has a unique pharmacodynamic advantages: high bio-utilization, high lung tissue concentration, high safety, low plasma protein binding rate.
has become one of the main drugs used in anti-infection treatment in many departments, widely used in respiratory, hematology, infectious diseases, surgery and other departments.
2020H1 China's public medical institutions terminal lynazine injection brand pattern source: China's public medical institutions terminal competition pattern Mi net data show that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal lynazole injections have maintained a 20% growth rate, sales in 2019 more than 1.8 billion yuan;
10 pharmaceutical companies such as Pfizer, Jiangsu Haussen Pharmaceuticals, Zhengda Tianqing Pharmaceuticals, Jiangsu Zhengda Fenghai Pharmaceuticals, etc.
, Pfizer has the largest market share, accounting for more than 50 per cent, followed by Jiangsu Haussen Pharmaceuticals with 33.58 per cent.
note that Pfizer's market share has declined in recent years, from more than 90 percent in 2016 to 55.56 percent in the first half of this year, as domestic drug companies have gained strength.
source: MED2.0 China Drug Review Database Up to now, lynazine glucose injection has been Jiangsu Hausen Pharmaceuticals and Jiangsu Zhengda Fenghai Pharmaceutical two enterprises have been evaluated, and before that, the product has not been evaluated by enterprises.
In addition, Zhejiang Pharmaceutical Xinchang Pharmaceutical Factory's consistency evaluation supplementary application in the review and approval (in the drug review center), Guangzhou Green Cross Pharmaceuticals, Shijiazhuang Four Drugs, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceuticals and other 4 enterprises to copy 4 categories of submitted listing applications are also in the review and approval (in the drug review center), after approval will be treated as a review.
source: official website of the State Drug Administration, Mi net database